Boston Scientific (NYSE:BSX) Price Target Raised to $130.00

Boston Scientific (NYSE:BSX) had its target price upped by analysts at Royal Bank Of Canada from $125.00 to $130.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 39.89% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company raised their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Robert W. Baird lifted their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $125.40.

Boston Scientific Price Performance

NYSE:BSX opened at $92.93 on Wednesday. The stock has a market capitalization of $137.76 billion, a PE ratio of 49.70, a P/E/G ratio of 1.86 and a beta of 0.67. Boston Scientific has a 1-year low of $85.98 and a 1-year high of $109.50. The firm has a fifty day simple moving average of $98.70 and a 200 day simple moving average of $101.42. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts expect that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 143,095 shares of company stock worth $14,228,950 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in the stock. Steph & Co. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the third quarter worth $25,000. Murphy & Mullick Capital Management Corp increased its position in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter valued at about $26,000. Finally, FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth about $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.